President Trump may be expecting a tremendous drop in prescription drug prices, but more than two dozen payers think otherwise: They foresee their per-unit acquisition costs rising between 3 percent and 5 percent annually over the next three years, according to a new survey by Cowen analysts.

Moreover, 13 percent of the payers attributed a substantial portion of those anticipated increases to more higher priced, newer medicines. By contrast, 40 percent of payers last year expected cost increases would be due to new therapies with high price tags.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy